PT3383385T - Regimes de dosagem de melflufeno para o cancro - Google Patents

Regimes de dosagem de melflufeno para o cancro

Info

Publication number
PT3383385T
PT3383385T PT168057925T PT16805792T PT3383385T PT 3383385 T PT3383385 T PT 3383385T PT 168057925 T PT168057925 T PT 168057925T PT 16805792 T PT16805792 T PT 16805792T PT 3383385 T PT3383385 T PT 3383385T
Authority
PT
Portugal
Prior art keywords
melflufen
cancer
dosing schemes
dosing
schemes
Prior art date
Application number
PT168057925T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55177548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3383385(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of PT3383385T publication Critical patent/PT3383385T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT168057925T 2015-12-01 2016-12-01 Regimes de dosagem de melflufeno para o cancro PT3383385T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1521217.8A GB201521217D0 (en) 2015-12-01 2015-12-01 Dosage regimens

Publications (1)

Publication Number Publication Date
PT3383385T true PT3383385T (pt) 2020-10-26

Family

ID=55177548

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168057925T PT3383385T (pt) 2015-12-01 2016-12-01 Regimes de dosagem de melflufeno para o cancro

Country Status (27)

Country Link
US (3) US20180369141A1 (enExample)
EP (3) EP3383385B2 (enExample)
JP (2) JP6878431B2 (enExample)
KR (2) KR20210092327A (enExample)
CN (1) CN108289876A (enExample)
AU (2) AU2016363591B2 (enExample)
BR (1) BR112018010012A8 (enExample)
CA (1) CA3003102C (enExample)
CY (1) CY1123469T1 (enExample)
DK (1) DK3383385T4 (enExample)
ES (1) ES2828033T5 (enExample)
FI (1) FI3383385T4 (enExample)
GB (1) GB201521217D0 (enExample)
HR (1) HRP20201632T4 (enExample)
HU (1) HUE051525T2 (enExample)
IL (2) IL259101A (enExample)
LT (1) LT3383385T (enExample)
MX (2) MX384724B (enExample)
PL (1) PL3383385T5 (enExample)
PT (1) PT3383385T (enExample)
RS (1) RS60986B2 (enExample)
RU (2) RU2020134307A (enExample)
SG (1) SG11201803551YA (enExample)
SI (1) SI3383385T2 (enExample)
SM (1) SMT202000567T1 (enExample)
WO (1) WO2017093443A1 (enExample)
ZA (2) ZA201802816B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019362389B2 (en) * 2018-10-18 2024-12-12 Oncopeptides Innovation Ab Compounds containing deuterium
EP4588484A3 (en) * 2019-01-28 2025-10-15 Sanofi-Aventis U.S. LLC Methods of treating multiple myeloma
CN114025753A (zh) * 2019-04-03 2022-02-08 肿瘤多肽有限公司 用美氟芬治疗al淀粉样变性
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) * 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
SE544998C2 (en) * 2021-01-13 2023-02-21 Bkmdcl Ab Peptide conjugates of melphalan for the treatment of cancer
EP4366721A1 (en) * 2021-07-08 2024-05-15 Oncopeptides Innovation AB Melflufen for use in the treatment of multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
RS56462B1 (sr) * 2011-04-28 2018-01-31 Oncopeptides Ab Liofilizovani preparat citotoksičnih dipeptida
EP2909690B1 (en) 2012-10-22 2017-07-19 Parker Hannifin Manufacturing Sweden AB Joystick for utility vehicles
JP6284945B2 (ja) * 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
EA032775B1 (ru) * 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10

Also Published As

Publication number Publication date
JP2019501881A (ja) 2019-01-24
IL301019B2 (en) 2025-12-01
ZA201802816B (en) 2021-07-28
EP3383385A1 (en) 2018-10-10
CA3003102A1 (en) 2017-06-08
AU2016363591A1 (en) 2018-06-28
MX384724B (es) 2025-03-14
MX2018006706A (es) 2018-08-01
HRP20201632T1 (hr) 2021-01-08
ES2828033T5 (es) 2024-04-04
EP3903777A1 (en) 2021-11-03
ES2828033T3 (es) 2021-05-25
US20250144023A1 (en) 2025-05-08
EP3383385B1 (en) 2020-07-29
FI3383385T4 (fi) 2023-11-01
SMT202000567T1 (it) 2020-11-10
HUE051525T2 (hu) 2021-03-01
EP3750534A1 (en) 2020-12-16
ZA202102438B (en) 2025-08-27
SG11201803551YA (en) 2018-05-30
CA3003102C (en) 2022-09-13
DK3383385T3 (da) 2020-10-12
PL3383385T3 (pl) 2021-05-04
GB201521217D0 (en) 2016-01-13
US20220047507A1 (en) 2022-02-17
RS60986B2 (sr) 2023-12-29
RU2018123718A (ru) 2020-01-09
RS60986B1 (sr) 2020-11-30
RU2020134307A (ru) 2020-11-27
PL3383385T5 (pl) 2023-12-18
IL259101A (en) 2018-06-28
MX2021008738A (es) 2021-08-24
US20180369141A1 (en) 2018-12-27
HRP20201632T4 (hr) 2023-11-10
KR20180087254A (ko) 2018-08-01
LT3383385T (lt) 2020-12-28
KR20210092327A (ko) 2021-07-23
BR112018010012A8 (pt) 2019-02-26
IL301019A (en) 2023-05-01
CY1123469T1 (el) 2022-03-24
RU2018123718A3 (enExample) 2020-04-02
AU2016363591B2 (en) 2020-12-10
CN108289876A (zh) 2018-07-17
NZ742548A (en) 2023-10-27
DK3383385T4 (da) 2023-11-06
WO2017093443A1 (en) 2017-06-08
EP3383385B2 (en) 2023-09-06
JP6878431B2 (ja) 2021-05-26
SI3383385T1 (sl) 2020-11-30
SI3383385T2 (sl) 2024-01-31
BR112018010012A2 (pt) 2018-11-21
JP2021088560A (ja) 2021-06-10
RU2734930C2 (ru) 2020-10-26
IL301019B1 (en) 2025-08-01
KR102279629B1 (ko) 2021-07-20
AU2021200436A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
PT3283527T (pt) Terapêutica de combinação para o cancro
IL254283A0 (en) Molecular profiling for cancer
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
BR112017008399A2 (pt) abordagem de imunoterapia de combinação para tratamento de câncer
DK3386954T3 (da) Dimere kontrastmidler
GB201522391D0 (en) Antibody molecules
PT3383385T (pt) Regimes de dosagem de melflufeno para o cancro
DK3242685T3 (da) Cxcr4-bindende molekyler
HUE055312T2 (hu) Közegkeverõ kamra
ZA201701450B (en) Small molecule inhibitors for cancer therapy
EP3359555A4 (en) DOSIERPLÄNE
EP3395436A4 (en) MICRO REACTOR
IL259864A (en) Monomaleimide-functionalized platinum compounds for cancer therapy
KR20180084835A (ko) 2성분 필라멘트
DK3277284T3 (da) Hidtil ukendte terapier mod kræft
DK3374357T3 (da) Disubstituerede diaryloxybenzoheterodiazol-forbindelser
EP3251522C0 (en) FUNCTIONAL FOOD
ITUB20153351A1 (it) Impianto ribaltatore di vasche di macchine impastatrici
DE112015005590A5 (de) Dosierpumpe
ES1140762Y (es) Union para bandejas portacables
ITUB20153343A1 (it) Impianto ribaltatore di vasche di macchine impastatrici
ES1135628Y (es) Monoboya para vertido controlado
IL258186A (en) Compositions having anti-fugetactic properties for treatment of cancer
ES1140283Y (es) Dispositivo de union para muletas
ES1148233Y (es) Cinta-faja para bebes